Skip to main content

Compartment Syndrome Traumatic Lower Extremity

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
Intramuscular administration of autologous BM-MNCsPhase 11 trial
Active Trials
NCT03880656Active Not Recruiting18Est. Jun 2026
MY01
MY01QC - Montréal
1 program
MY01 Continuous Compartmental Pressure MonitorN/A1 trial
Active Trials
NCT04012723Completed100Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Oregon TherapeuticsIntramuscular administration of autologous BM-MNCs
MY01MY01 Continuous Compartmental Pressure Monitor

Clinical Trials (2)

Total enrollment: 118 patients across 2 trials

NCT03880656Oregon TherapeuticsIntramuscular administration of autologous BM-MNCs

BM-MNCs for Lower Extremity Compartment Syndrome Injury

Start: Dec 2019Est. completion: Jun 202618 patients
Phase 1Active Not Recruiting
NCT04012723MY01MY01 Continuous Compartmental Pressure Monitor

Clinical Trial of a New Device for Real-Time Muscle Pressure Measurements in Patients at Risk for Acute Compartment Syndrome

Start: Nov 2020Est. completion: Mar 2023100 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.